Business
TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase
BERLIN, September 22, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announces today that its half year results will be published on 30 October 2025. The closed period for insiders of the Company will start next week, 30 days before the publication of the half-year results on October 30, 2025.
About this update from Tme Pharma N.v.
[{"type":"text","content":"BERLIN, September 22, 2025--(BUSINESS WIRE)--Regulatory News:","length":61,"tagName":"p"},{"type":"text","content":"TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announces today that its half year results will be published on 30 October 2025. The closed period for insiders of the Company will start next week, 30 days before the publication of the half-year results on October 30, 2025.","length":392,"tagName":"p"},{"type":"text","content":"TME Pharma additionally announces that it has received notification that Diede Van Den Ouden, Chief Executive Officer and a Person Discharging Managerial Responsibilities ("PDMR"), has purchased an additional 300,000 ordinary shares in the Company at an average price per share of €0.0927. The shares were acquired through an on-market transaction on Euronext Growth Paris on Friday 19 September 2025. Following this transaction, Mr Van Ouden holds a total of 2,300,000 ordinary shares.","length":496,"tagName":"p"},{"type":"text","content":"Statement from the CEO","length":22,"tagName":"p"},{"type":"text","content":""My share purchases are an indication of my strong belief in the Company’s future, financial position and ability to progress its research and development activities. I expressly reserve the right, when permitted and under appropriate circumstances, to purchase shares in the Company in the market. I am fully aligned with fellow shareholders, having elected only a modest cash remuneration, because the true success of this project rests on the future value of my equity." said Van den Ouden, CEO.","length":508,"tagName":"p"},{"type":"text","content":""Although we have not yet disclosed concrete news, I am pleased with the progress made during the first three months of my tenure including the aggressive cost-saving measures, which have reduced monthly operating expenses to approximately €100,000 per month, enabling the Company to report a cash balance of €2.35 million at September 1, 2025. The transition to a virtual model has been smooth—the former team remains available to support us and continues to be motivated to succeed. We are actively engaging in discussions with a broad spectrum of potential partners relating to the Company’s research and ...